Changing Landscape of Treatment Options for ALL with CD19, CD22 Monoclonal Antibodies and AML with IDH1/2, FLT3, CD33 and Hedgehog Pathway Targeted Agents

Released On
September 17, 2019

Expires On
September 17, 2020

Media Type

Completion Time
60 minutes


Scroll to the Bottom of this Information to Begin this Course

Jointly provided by Amedco and CancerNet


This activity is supported by educational funding provided by Amgen.

Target Audience

This webcast is designed to meet the educational needs of hematologists/oncologists, physician assistants, nurse practitioners, registered nurses, pharmacists, fellows in training on the latest advances in the diagnosis, and treatment of acute leukemia (ALL and AML).

Program Overview

This webcast is intended to improve care of patients with acute leukemia (ALL and AML) by accelerating adoption of new guidelines and evidence-based practice change. In-depth discussion of novel agents at various stages of clinical development will be given significant focus. This Internet CME activity is designed to provide clinical decision-making strategies for integration of novel therapeutic options.

Learning Objectives

Upon completion of this activity, participants should be better able to:

  • Interpret cytogenetic and molecular alterations in the diagnosis and treatment with CD19, CD22 mAb and anti-CD19 CAR T-cell based therapies for relapsed/refractory ALL
  • Discuss molecular genetic mutations, disease classification, prognostic stratification and treatment options with IDH1/2, FLT3, CD33 and Hedgehog pathway targeted agents in AML

Credit Available

  • Physicians — maximum of 1 AMA PRA Category 1 Credit(s)
  • Nurses — 1 contact hours.

All other health care professionals completing this course will be issued a statement of participation.


Elias Jabbour, MD

Department of Leukemia
The University of Texas MD Anderson Cancer Center
Houston, TX

Courtney DiNardo, MD

Department of Leukemia
The University of Texas MD Anderson Cancer Center
Houston, TX

Physicians and Nurses

In support of improving patient care, this activity has been planned and implemented by Amedco LLC and CancerNet. Amedco LLC is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Credit Designation Statement – Amedco LLC designates this enduring material activity for a maximum of 1 AMA PRA Category 1 Credits™ for physicians and 1 contact hour for nurses. Learners should claim only the credit commensurate with the extent of their participation in the activity.

Disclosures of Conflicts of Interest - Faculty or Presenter

Name of Faculty or Presenter Reported Financial Relationship
Elias Jabbour, MD Research Grants: Amgen, Pfizer, Takeda, Adaptive, Novartis, Spectrum, AbbVie, BMS
Consultant/Advisory Board: Pfizer, Takeda, Amgen, AbbVie, BMS
Courtney DiNardo, MD Research Support (to institution): AbbVie, Agios, Bayer, Calithera, Celgene, Daiichi-Sankyo, Novartis
Consultant/Advisory Board: AbbVie, Agios, Celgene, Daiichi-Sankyo, Jazz, Syros, Notable Labs

Disclosures of Conflicts of Interest - Planner or Manager

Name of Planner or Manager Reported Financial Relationship
Kamatham A. Naidu, PhD (CancerNet) No relevant financial relationships
Brian Waggoner (CancerNet) No relevant financial relationships

Method of Participation and Request for Credit

There are no fees for participating and receiving CME/CE credit for this webcast. During the period September 17, 2019 through September 17, 2020, participants must read all the material and study the educational webcast.

Instructions for Course Participation

This webcast includes text, graphics, and may include multimedia features. There are no fees for participating in or receiving credit for this webcast.

Click on all of the "medical education webcast" links and review the content presented. You must view all of the content to proceed to the post-test.

Read, complete, and submit answers to the post-test questions and evaluation questions online. You must answer all missed questions until you get them correct.

Participants must receive a test score of 70% in order to proceed to the course evaluation, and they must respond to all evaluation questions to receive a certificate of completion.

If needed, you may save your answers and return to complete your course at a later date. You can find your saved course by selecting "Your Course History" on the left navigation bar. Then select "View" next to the course you would like to complete.

Hardware and Software Requirements

This site is best viewed with an HTML5 compatible browser. You can visit the independent (3rd party) site to determine if you have the latest version of your browser.

Certain educational activities may require additional software to view multimedia, presentation, or printable versions of their content. That software may be: Adobe Flash, Apple QuickTime, Adobe Acrobat, Microsoft PowerPoint, Windows Media Player, and Real Networks Real One Player.

Disclosure of Unlabeled Use

Amedco, LLC. requires that faculty participating in any CME activity disclose to the audience when discussing any unlabeled or investigational use of any commercial product or device not yet approved for use in the United States.

During this activity, Dr. Jabbour and Dr. DiNardo may mention the use of medications for both FDA-approved and non-approved indications


Amedco makes every effort to develop CME activities that are scientifically based.

This activity is designed for educational purposes. Participants have a responsibility to utilize this information to enhance their professional development to improve patient outcomes. Conclusions drawn by the participants should be derived from careful consideration of all available scientific information. The participant should use his/her clinical judgment, knowledge, experience, and diagnostic decision-making before applying any information, whether provided here or by others, for any professional use.

Questions pertaining to the content of this activity - Email: or call 972-459-5222

Questions pertaining to the issuing of your CE certificate - Email:

CME Provider Privacy Policy and Contact Information

Amedco observes privacy and confidentiality of CE information and personal information of CE participants. Third parties receive only aggregated data about CE activities that are relevant to their interests and/or the activities they support.